Brief: Strides Pharma Science Says Biolexis, Akston Biosciences Announce Encouraging Top-Line Results From Phase II/III Trial Of Thermostable COVID-19 Vaccine

Strides Pharma Science

24/06/2022 06:29

June 24 (Reuters) - Strides Pharma Science Ltd  SRID.NS :
    * STRIDES PHARMA SCIENCE - BIOLEXIS, AKSTON BIOSCIENCES ANNOUNCE  ENCOURAGING TOP-LINE
RESULTS
FROM PHASE II/III TRIAL OF THERMOSTABLE 2ND GEN COVID-19 VACCINE
    * STRIDES PHARMA SCIENCE - INTERIM ANALYSIS SHOWS A 91% SEROCONVERSION RATE
    * STRIDES PHARMA SCIENCE - VACCINE WAS WELL TOLERATED, WITH NO SIGNIFICANT SAFETY ISSUES
REPORTED
    * STRIDES PHARMA SCIENCE - VACCINE TO BE PRODUCED AT STELIS BIOPHARMA

Source text for Eikon:  ID:nBSE5kl1RS 
Further company coverage:  SRID.NS 

 ((Reuters.Briefs@thomsonreuters.com;))